Summary & Overview
CPT 88344: Multiplex Immunohistochemistry or Immunocytochemistry Procedure
CPT code 88344 is a key billing code for multiplex immunohistochemistry or immunocytochemistry procedures performed in pathology laboratories. This code is used when multiple antibody stains are applied to a single specimen, enabling more comprehensive diagnostic information for conditions such as cancer. The procedure is essential for accurate disease characterization and guides clinical decision-making across a range of specialties.
Major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare recognize and reimburse for CPT code 88344. The code is relevant for both anatomic and clinical pathology practices, and is frequently utilized in laboratory settings for the evaluation of tissue samples. Readers will gain insight into payer coverage, clinical indications, and policy updates related to this code. The publication also provides context on associated modifiers, taxonomies, and ICD-10 diagnoses, as well as related CPT codes for single antibody stain procedures.
This summary offers a comprehensive overview of CPT code 88344, highlighting its clinical significance, payer landscape, and billing considerations. The information is designed to inform stakeholders about current benchmarks and regulatory updates impacting pathology and laboratory services nationwide.
CPT Code Overview
CPT code 88344 represents immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure. This procedure is a specialized laboratory test used in pathology to detect specific antigens in cells of a tissue section by using multiplex antibody stains. It is commonly performed in facility-based pathology laboratories and plays a critical role in diagnosing and characterizing various diseases, including cancers. The service type is Pathology / Laboratory, and the typical site of service is a laboratory setting where specimens are processed and analyzed by pathologists.
Clinical & Coding Specifications
Clinical Context
A patient presents with a tissue specimen requiring evaluation for possible malignancy, such as a breast, lung, prostate, colon, or liver lesion. The specimen is sent to a facility-based pathology laboratory. The pathologist determines that multiplex immunohistochemistry or immunocytochemistry is necessary to assess multiple biomarkers simultaneously. This procedure is performed to aid in diagnosis, tumor classification, or to guide treatment decisions. The workflow involves specimen processing, multiplex antibody staining, and interpretation by a pathologist, often documented in a pathology report.
Coding Specifications
-
Modifier
26: Used to indicate the professional component, representing the pathologist's interpretation and report. -
Modifier
TC: Used for the technical component, covering specimen processing, staining, and laboratory work. -
Modifier
59: Indicates a distinct procedural service, used when multiple procedures are performed that are not normally reported together. -
Modifier
91: Used for repeat clinical diagnostic laboratory tests on the same patient, same day.
| Provider Taxonomy Code | Specialty Name |
|---|---|
207ZP0102X | Anatomic Pathology & Clinical Pathology |
207ZP0104X | Cytopathology |
207ZP0105X | Dermatopathology |
207ZP0101X | Blood Banking & Transfusion Medicine |
207ZP0103X | Forensic Pathology |
Related Diagnoses
-
C50.911: Malignant neoplasm of unspecified site of right female breast- Relevant for immunohistochemistry to identify breast cancer markers.
-
C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung- Used to evaluate lung cancer specimens for diagnostic and prognostic markers.
-
D49.2: Neoplasm of unspecified behavior of bone, soft tissue, and skin- Applied when the nature of the neoplasm is unclear, requiring further immunostaining.
-
C61: Malignant neoplasm of prostate- Utilized for prostate cancer diagnosis and classification.
-
C18.9: Malignant neoplasm of colon, unspecified- Used for colon cancer specimens to assess relevant biomarkers.
-
D05.10: Carcinoma in situ of unspecified breast- Relevant for early-stage breast cancer, where multiplex staining may help in diagnosis.
-
C22.0: Liver cell carcinoma- Used for liver cancer specimens to identify specific tumor markers.
Related CPT Codes
-
88341: Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure. Used for the first single antibody stain on a specimen. -
88342: Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure). Used for each additional single antibody stain after the initial. -
88344: The primary code for multiplex antibody stain procedures, where multiple antibodies are applied simultaneously to a specimen.
In clinical workflow, 88341 and 88342 are used for single antibody stains, while 88344 is used for multiplex stains. These codes may be used together if both single and multiplex stains are performed on the same specimen, but only one unit per separately identifiable antibody per specimen is allowed.
National Reimbursement Benchmarks
Medicare's national mean rate for CPT code 88344 is $120.79, which is slightly higher than the BUCA (average commercial) mean rate of $114.56. Among the major commercial payers, Blue Cross Blue Shield has the highest mean rate at $129.68, while Cigna is the lowest at $112.04.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare shows the widest spread ($131.00), indicating substantial variability in rates, while UnitedHealth Group has the tightest range ($54.67), suggesting more consistent reimbursement levels. Blue Cross Blue Shield and Cigna also exhibit wide dispersions, with $104.88 and $92.33 respectively.
The table and chart below present the full breakdown of national benchmarks for CPT code 88344 across all major payers.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.